LLY

989.25

+4.39%↑

JNJ

221.72

+0.27%↑

ABBV

203.74

+1.29%↑

UNH

379.92

+0.13%↑

AZN

184.64

+1.27%↑

LLY

989.25

+4.39%↑

JNJ

221.72

+0.27%↑

ABBV

203.74

+1.29%↑

UNH

379.92

+0.13%↑

AZN

184.64

+1.27%↑

LLY

989.25

+4.39%↑

JNJ

221.72

+0.27%↑

ABBV

203.74

+1.29%↑

UNH

379.92

+0.13%↑

AZN

184.64

+1.27%↑

LLY

989.25

+4.39%↑

JNJ

221.72

+0.27%↑

ABBV

203.74

+1.29%↑

UNH

379.92

+0.13%↑

AZN

184.64

+1.27%↑

LLY

989.25

+4.39%↑

JNJ

221.72

+0.27%↑

ABBV

203.74

+1.29%↑

UNH

379.92

+0.13%↑

AZN

184.64

+1.27%↑

Home・Akcijų sąrašas・Xencor Inc

Xencor Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

13.37 3.89

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.7

Max

13.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	92M 85M
Pardavimai	7.2M 28M
Pelnas, tenkantis vienai akcijai	-0.09
Pelno marža	302.738
Darbuotojai	260
EBITDA	1.4M 5.7M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+101.48% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	164M 990M
Ankstesnė atidarymo kaina	9.48
Ankstesnė uždarymo kaina	13.37

Naujienos nuotaikos

By Acuity

50%

153 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

7.87 / 10.84 Palaikymas ir pasipriešinimas

Xencor Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-10 23:47; UTC

Rinkos pokalbiai

Gold Falls on Renewed Inflation Concerns -- Market Talk

2026-05-10 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026-05-10 23:38; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

2026-05-10 23:14; UTC

Rinkos pokalbiai

Australia's Political Map Continues to Be Redrawn -- Market Talk

2026-05-10 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium: Expects Deal to Close in 1Q FY27

2026-05-10 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

2026-05-10 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

2026-05-10 10:21; UTC

Uždarbis

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

2026-05-09 06:05; UTC

Uždarbis

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

2026-05-08 23:55; UTC

Uždarbis

Review & Preview: Still Going Strong -- Barrons.com

2026-05-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 20:49; UTC

Uždarbis

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026-05-08 20:25; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Net $115M

2026-05-08 19:20; UTC

Rinkos pokalbiai

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026-05-08 19:18; UTC

Uždarbis

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026-05-08 19:16; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:08; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:05; UTC

Uždarbis

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026-05-08 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026-05-08 18:51; UTC

Uždarbis

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026-05-08 18:49; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 18:41; UTC

Uždarbis

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026-05-08 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026-05-08 17:14; UTC

Uždarbis

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026-05-08 17:04; UTC

Rinkos pokalbiai

Zcash Caps Off Parabolic Week -- Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Xencor Inc Prognozė

Kainos tikslas

By TipRanks

101.48% į viršų

12 mėnesių prognozė

Vidutinis 25.91 USD 101.48%

Aukščiausias 43 USD

Žemiausias 13 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xencor Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Xencor Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

7.87 / 10.84Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

153 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.